Thus, modulation of utrophin levels may be an alternative therapeutic approach for DMD patients (Guiraud and Davies, 2017; Soblechero-Martín et al, 2021; Szwec et al, 2024). The gene discussed is UTRN; the disease is Duchenne muscular dystrophy.